Improvement of Neurodegenerative Disease after Use of Vemurafenib in Refractory BRAF V600E-Mutated Langerhans Cell Histiocytosis: A Case Report
Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder characterized by heterogenous lesions infiltrated with CD1a+/CD207+ cells. Although LCH has a relatively good prognosis, the prognosis for patients with LCH refractory to standard chemotherapy is poor. Neurodegenerative LCH (ND-LCH)...
Saved in:
Main Authors: | Young Kwon Koh (Author), Su Hyun Yoon (Author), Sung Han Kang (Author), Hyery Kim (Author), Ho Joon Im (Author), Pyeong Hwa Kim (Author), Ah Young Jung (Author), Kyung-Nam Koh (Author) |
---|---|
Format: | Book |
Published: |
The Korean Society of Pediatric Hematology-Oncology,
2022-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of BRAF inhibitor (Vemurafenib) in a child with Refractory Langerhans cell histiocytosis
by: Anil Sharma, et al.
Published: (2017) -
Adult‐onset BRAF V600E‐related multisystem Langerhans cell histiocytosis treated with vemurafenib
by: Lisa Denise A. Encarnacion‐Mangubat, et al.
Published: (2024) -
Targeted therapy- Vemurafinib in BRAF V600E positive Langerhan cell histiocytosis
by: Mohammed Naseer, et al.
Published: (2017) -
Targeted Therapy- Vemurafinib in BRAF V600E positive langerhan cell histiocytosis
by: Mohammed Naseer, et al.
Published: (2017) -
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
by: Sara V. Bates, et al.
Published: (2013)